Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
about
Multipurpose prevention technologies: the future of HIV and STI protectionA Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola VirusHIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trialEffectiveness and safety of oral HIV preexposure prophylaxis for all populationsRisk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in DeliveryTranslating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessationSafety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant PartnershipsNondaily preexposure prophylaxis for HIV prevention.Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy.Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention.Perceptions among Dutch men who have sex with men and their willingness to use rectal microbicides and oral pre-exposure prophylaxis to reduce HIV risk--a preliminary study.Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.Tackling HIV and AIDS: contributions by non-human primate models.Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study.Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.PrEP Implementation Science: State-of-the-Art and Research Agenda.Semen as the Way Forward to Understand HIV-1 Transmission.Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.Setting the stage for expanding HIV pre-exposure prophylaxis use in Canada.Scale up of PrEP integrated in public health HIV care clinics: a protocol for a stepped-wedge cluster-randomized rollout in Kenya
P2860
Q26827796-916F2733-2921-4B7B-8D8F-CEF621F004D4Q28552295-5C4F62E4-C351-492B-9A69-6F47D708B087Q33848307-297611A9-B208-4E3F-BAB2-30257C18DCE7Q34677217-CEF4C680-9A05-4001-9A35-EE3054957322Q35473551-E8FBA980-14B3-4891-825A-36B5A87C3641Q35541521-B22C15A4-9F6F-49FC-BB94-5A4C1D19BFC6Q35875746-35594AC4-C2DB-46C3-BE37-983A61511431Q35875751-196AD91E-AB0E-4DA2-80FC-1EB96B64016BQ36438778-5DAEB2FA-D216-43FC-95B9-2120BE6E18B3Q36586078-35BD6D44-A759-4DDA-88DC-7D1C1BDB4955Q36602040-202173B2-2824-4DD7-9692-0A3E44B08673Q36669377-3627FA0C-E498-4097-B88C-5BD76F44589CQ36739989-E870980B-0454-4A10-8287-043AE34F4EAAQ36888077-1E5574BF-2BB7-4C31-BA00-87567356E22DQ37033062-66501E8C-9797-4914-BA4B-90D83473C021Q37126494-E353A3D0-3D49-4D9B-955A-B4E3F4A88ACAQ37341579-34872573-77F0-427A-B641-43E0C4A9E085Q37409772-4105A49A-1C9D-42F0-954C-6EF82E259185Q38667599-2E1F095E-4AD9-49EE-BC10-60556E6591B6Q38849706-DF284D0B-CF37-4076-A28F-8D451C94AC48Q38850925-67DC6851-EB73-4B98-BB5B-51F77A103ED8Q39217013-C3D5F0C3-604B-4054-BF73-AFAC1D9CF37FQ39488594-0066BF86-1E16-4B97-AB4B-C8122A28324DQ40191155-F6F5E08E-1AAF-4564-AA66-AD8F4111FC7FQ40358789-446104C4-1DE3-4CF3-86FE-22BB4258D48DQ40377358-6A157154-065E-4436-A08A-DC6FDCDCAE24Q42376936-A6D70A47-FAB5-4EEE-8BC9-8C039623DD09Q43201094-C719577F-9AAA-41EA-891A-6080636B4D91Q43241737-D21C2837-CBE5-4B5A-8244-B02357C30A5DQ44238958-B1AE624A-E7D8-4DCF-87CE-44621435526FQ47140417-D319BBE4-6A02-4312-B257-48E135AE7C2DQ47580343-D4EB6FFE-0583-404A-A4EA-E5DC6EECF5BDQ55334249-64B6653C-1319-4F8C-BACD-6431005B97DBQ58765180-9AA8B134-5235-428B-82DE-7EDDB4C03407
P2860
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@ast
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@en
type
label
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@ast
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@en
prefLabel
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@ast
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@en
P2093
P2860
P50
P1476
Single-agent tenofovir versus ...... , double-blind, phase 3 trial.
@en
P2093
Carey Farquhar
Craig Hendrix
David Bangsberg
Edwin Were
Elioda Tumwesigye
James D Campbell
James Kiarie
Jared M Baeten
Jessica E Haberer
Jonathan Wangisi
P2860
P304
P356
10.1016/S1473-3099(14)70937-5
P50
P577
2014-10-07T00:00:00Z